Nirmatrelvir/ritonavir: real world drug–drug interaction management experience-Reference-Cited by-同舟云学术

Nirmatrelvir/ritonavir: real world drug–drug interaction management experience

Published:2024-08-22 Issue: Volume: Page:1-3
ISSN:1478-7210
Container-title:Expert Review of Anti-infective Therapy
language:en
Short-container-title:Expert Review of Anti-infective Therapy

Author:

Bukhari Shahid¹^ORCID,Hughes Stephen¹,Mughal Nabeela¹,Moore Luke S P¹²³^ORCID,Davies Gary¹,Vargas Zhang Adrian²,Ng Megan²,Karagozlu Zekiye²,Boffito Marta¹²^ORCID

Affiliation:

1. Chelsea and Westminster Hospital Foundation Trust, London, UK

2. Imperial College London, London, UK

3. North West London Pathology, Imperial College Healthcare NHS Trust, London, UK

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14787210.2024.2389884

Reference7 articles.

1. World Health Organisation. Therapeutics and COVID-19: living guideline. Geneva (CH): World Health Organisation; c2020–2023 [updated 2023 Jan 13; [cited 2024 Jan 12]. Section 7 [p.14]. Available from https://iris.who.int/bitstream/handle/10665/373975/WHO-2019-nCoV-therapeutics2023.2-eng.pdf?sequence=1

2. NIH. Ritonavir-Boosted Nirmatrelvir (Paxlovid) [internet]. Bethesda (MD): National Institutes of Health; [updated 2024 Feb 29; cited 2023 Jul 21]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir–paxlovid-/

3. Recommendations for the Management of Drug–Drug Interactions Between the COVID ‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

4. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?

5. University of Liverpool: COVID-19 drug interactions [internet]. Liverpool (UK): University of Liverpool; [cited 2023 Dec]. Available from: https://www.covid19-druginteractions.org/checker